Jawaid Younus
YOU?
Author Swipe
View article: The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis
The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis Open
Background: Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despite the potentially life-threatening adverse events caused by anthracyclines. Commonly, the combination of docetaxel and …
View article: Primary Prophylaxis Lapelga® in Early Breast Cancer: A Real-World Experience
Primary Prophylaxis Lapelga® in Early Breast Cancer: A Real-World Experience Open
Background: Lapelga® was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category. We explored …
View article: Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial
Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial Open
Background Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. Methods We prospectively collected CTC data from p…
View article: The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (<scp>QUINTETT</scp>): Randomized parallel clinical superiority trial
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (<span>QUINTETT</span>): Randomized parallel clinical superiority trial Open
Background We compared the health‐related quality of life (HRQOL) in patients undergoing trimodality therapy for resectable stage I‐III esophageal cancer. Methods A total of 96 patients were randomized to standard neoadjuvant cisplatin and…
View article: Circulating Tumor Cells Detected in Follow-up Predict Survival Outcomes in Tri- modality Management of Advanced Non-Metastatic Esophageal Cancer: A Secondary Analysis of the QUINTETT Randomized Trial
Circulating Tumor Cells Detected in Follow-up Predict Survival Outcomes in Tri- modality Management of Advanced Non-Metastatic Esophageal Cancer: A Secondary Analysis of the QUINTETT Randomized Trial Open
Background: Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. Methods: We prospectively collected CTC data from…
View article: Contralateral Breast Cancer With Multiple Primary Neoplasms in a Patient With Neurofibromatosis Type 1: A Case Report and Review of the Literature
Contralateral Breast Cancer With Multiple Primary Neoplasms in a Patient With Neurofibromatosis Type 1: A Case Report and Review of the Literature Open
View article: CareTrack: an Application-Based Method of Documentation for Improving Communication in Cancer Care
CareTrack: an Application-Based Method of Documentation for Improving Communication in Cancer Care Open
A patient being able to accurately understand and recall medical information correctly has been shown to improve outcomes.However, many studies suggest that patient understanding about the disease and its management in oncology tends to be…
View article: MA14.11 CareTrack: An Application-Based Method of Documentation for Improving Patient Communication in Cancer Care
MA14.11 CareTrack: An Application-Based Method of Documentation for Improving Patient Communication in Cancer Care Open
View article: Phase I Study of Concurrent and Consolidation Cisplatin and Docetaxel Chemotherapy with Thoracic Radiotherapy in Non-Small Cell Lung Cancer
Phase I Study of Concurrent and Consolidation Cisplatin and Docetaxel Chemotherapy with Thoracic Radiotherapy in Non-Small Cell Lung Cancer Open
Background: We designed a phase I study of concurrent chemoradiotherapy (CCRT) with docetaxel (D) and cisplatin (C), followed by consolidation DC, for unresectable stage III non-small cell lung cancer (NSCLC). Methods: Patients with histol…
View article: Functional Lung Avoidance for Individualized Radiation Therapy (FLAIR): Results of a Randomized, Double-Blind Clinical Trial
Functional Lung Avoidance for Individualized Radiation Therapy (FLAIR): Results of a Randomized, Double-Blind Clinical Trial Open
View article: 242: Phase I Study of Cisplatin/Docetaxel Chemotherapy with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
242: Phase I Study of Cisplatin/Docetaxel Chemotherapy with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Open
View article: The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study
The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: A pilot study Open
Background: Peripheral neuropathy is a common side effect induced by chemotherapy agents like Cisplatin, Paclitaxel andDocetaxel. At present, there is no preventive strategy available against the development of neuropathy. This pilot study…
View article: Male Breast Cancer Prognostic Factors Versus Female Counterparts with Propensity Scores and Matched-Pair Analysis
Male Breast Cancer Prognostic Factors Versus Female Counterparts with Propensity Scores and Matched-Pair Analysis Open
This large series showed that MBC and FBC survivals are not similar, with MBC having a worse outcome. The finding of this study needs confirmation from a complete prospective database.
View article: Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers’ experience
Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers’ experience Open
Early breast cancer treatment with dose dense Adriamycin-Cyclophosphamide and Paclitaxel (AC-P) has been shown to increase survival. However, it is commonly associated with neutropenia, anemia or both. This retrospective chart review study…